Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)

Study acronym: ENABLE
StatusRecruiting
PhasePhase 4
Started

Record status This record was last updated June 3, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Prostate cancer often leads to bone metastases, which require adequate pain management with opioids such as oxycodone. This study investigates whether abiraterone - a drug used in the treatment of prostate cancer - affects the pharmacokinetics of oxycodone in order to improve pain management.
Trial Details
NCT Number NCT07001709
Lead Sponsor Deventer Ziekenhuis
Conditions
(from sponsor)		 Prostate Cancer, Pain Cancer
Related terms Cancer Pain, Prostatic Neoplasms
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov